The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Does The Market Size Of The Deoxycholic Acid Obesity Drugs Market Compare Between 2026 And 2030?
The deoxycholic acid obesity drugs market has experienced rapid expansion in its size during recent years. It is projected to increase from $0.5 billion in 2025 to $0.57 billion in 2026, maintaining a compound annual growth rate (CAGR) of 14.4%. This growth observed in the historic period can be attributed to several factors, including increasing consumer awareness of aesthetic treatments, the expansion of medical aesthetics clinics, a rising acceptance of minimally invasive procedures, the availability of approved deoxycholic acid formulations, and a growth in disposable income.
The deoxycholic acid obesity drugs market is projected to experience swift expansion over the coming years, with its size anticipated to reach $0.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.1%. This growth during the forecast period is attributable to several factors, including the escalating demand for tailored aesthetic treatments, the proliferation of combination aesthetic protocols, a heightened emphasis on body contouring procedures, increasing investments in innovative aesthetic drugs, and deeper market penetration in developing regions. Key trends expected within this period encompass the growing acceptance of non-surgical methods for fat reduction, an increased call for injectable aesthetic solutions, the ongoing advancement of combined lipolytic therapies, the broadening of clinic-based services for body contouring, and a stronger focus on achieving aesthetic results customized to individual patients.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28192&type=smp
What Leading Drivers Are Supporting The Deoxycholic Acid Obesity Drugs Market Expansion?
The increasing prevalence of obesity is projected to fuel the expansion of the deoxycholic acid obesity drug market. Obesity rates indicate the proportion of a population categorized as overweight or obese based on their body mass index (BMI). The rise in these rates is attributed to unhealthy eating habits, such as a high consumption of processed foods and sugary beverages, which results in the accumulation of excess body fat. Deoxycholic acid obesity drugs contribute to reducing obesity by breaking down and removing surplus fat cells, thereby achieving targeted fat reduction and a better body shape. For example, the Office for Health Improvement and Disparities, a UK government body, reported in May 2025 that an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity from 2023 to 2024, an increase from 64.0% in 2022 to 2023. Consequently, the growing obesity rates are propelling the deoxycholic acid obesity drug market forward.
How Are Different Segments Classified In The Deoxycholic Acid Obesity Drugs Market Segment Analysis?
The deoxycholic acid obesity drugs market covered in this report is segmented –
1) By Drug Type: ATX-101 (Deoxycholic Acid Injection Or Kybella Or Belkyra), Experimental Or Compounded Deoxycholic Acid Formulations, Combination Therapies, Oral Deoxycholic Acid Products
2) By Formulation: Injectable, Topical
3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies
4) By Application: Submental Fat Reduction, Abdominal Fat Reduction, Thighs Arms And Flanks, Lipomas And Localized Fat, Cellulite Management
5) By End-User: Aesthetic Clinics, Dermatology Clinics, Plastic Surgery Centers, Hospitals, Home Administration
Subsegments:
1) By ATX-101 (Deoxycholic Acid Injection or Kybella or Belkyra): Standard Injectable, High-Purity Formulations, Combination Injection Therapies
2) By Experimental Or Compounded Deoxycholic Acid Formulation: Clinical Trial Formulations, Compounded Customized Formulations
3) By Combination Therapies: Deoxycholic Acid + Lipolytic Agents, Deoxycholic Acid + Enzyme Therapy
4) By Oral Deoxycholic Acid Products: Capsules, Tablets, Liquid Formulations
What Market Trends Are Affecting The Deoxycholic Acid Obesity Drugs Market?
Leading companies in the deoxycholic acid obesity drug market are concentrating their efforts on developing advanced products, such as injectable deoxycholic acid obesity drugs, to enhance treatment efficacy and improve patient outcomes. Injectable deoxycholic acid obesity drugs utilize deoxycholic acid, a substance known for breaking down fat cells, and are administered as an injection to specifically target and reduce fat in certain areas. For instance, in March 2024, LG Chem Ltd., a South Korea-based chemicals company, introduced Bellacholine for the reduction of submental fat. This is a nonsurgical injection designed to reduce moderate to severe submental fat (double chin) by safely destroying fat cells using deoxycholic acid. It offers advantages including a body-compatible pH, minimal sedimentation, and the promotion of skin elasticity through collagen synthesis.
Who Are The Companies Driving Activity In The Deoxycholic Acid Obesity Drugs Market?
Major companies operating in the deoxycholic acid obesity drugs market are AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, Curia Global Inc., Daewoong Pharmaceutical Co. Ltd., Actylis, ICE Pharma, Cayman Chemical Company, Nacalai Tesque Inc., Sichuan Huiyu Pharmaceutical, Conscientia Industrial, Manus Aktteva Biopharma LLP, Jeevan Chemicals & Pharmaceuticals, Anhui Chem-Bright Bioengineering Co. Ltd., GlpBio Technology LLC, Legere Pharmaceuticals, Otto Chemie Pvt. Ltd., BOC Sciences, Guangzhou Green Cross Pharmaceutical, Prodotti Chimici e Alimentari S.P.A
Get The Full Deoxycholic Acid Obesity Drugs Market Report:
Which Region Accounts For The Largest Portion Of The Deoxycholic Acid Obesity Drugs Market?
North America was the largest region in the deoxycholic acid obesity drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxycholic acid obesity drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Deoxycholic Acid Obesity Drugs Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Deoxycholic Acid Obesity Drugs Market 2026, By The Business Research Company
Metabolic Disorders Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Weight Loss Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/weight-loss-drugs-global-market-report
Weight Loss Supplements Market Report 2026
https://www.thebusinessresearchcompany.com/report/weight-loss-supplements-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model